Riederer P - Search Results

1

[Pathogenesis and neuroprotective therapy trial in chronic degenerative diseases. Status of antioxidants].

Gerlach M, Riederer P. Gerlach M, et al. Among authors: riederer p. Med Klin (Munich). 1996 Mar 15;91(3):163-70. Med Klin (Munich). 1996. PMID: 8628203 Review. German. No abstract available.

2

Time sequences of dopaminergic cell death in Parkinson's disease: indications for neuroprotective studies.

Gerlach M, Riederer PF. Gerlach M, et al. Among authors: riederer pf. Adv Neurol. 1999;80:219-25. Adv Neurol. 1999. PMID: 10410725 Review. No abstract available.

3

The relevance of iron in the pathogenesis of Parkinson's disease.

Götz ME, Double K, Gerlach M, Youdim MB, Riederer P. Götz ME, et al. Among authors: riederer p. Ann N Y Acad Sci. 2004 Mar;1012:193-208. doi: 10.1196/annals.1306.017. Ann N Y Acad Sci. 2004. PMID: 15105267 Review.

4

Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease.

Riederer P, Gerlach M, Müller T, Reichmann H. Riederer P, et al. Parkinsonism Relat Disord. 2007 Dec;13(8):466-79. doi: 10.1016/j.parkreldis.2007.06.015. Epub 2007 Oct 4. Parkinsonism Relat Disord. 2007. PMID: 17919963 Review.

5

Role of iron in 6-hydroxydopamine neurotoxicity.

Double KL, Riederer PF, Gerlach M. Double KL, et al. Among authors: riederer pf. Adv Neurol. 1999;80:287-96. Adv Neurol. 1999. PMID: 10410733 Review. No abstract available.

6

MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease.

Gerlach M, Riederer P, Przuntek H, Youdim MB. Gerlach M, et al. Among authors: riederer p. Eur J Pharmacol. 1991 Dec 12;208(4):273-86. doi: 10.1016/0922-4106(91)90073-q. Eur J Pharmacol. 1991. PMID: 1815982 Review.

7

Altered brain metabolism of iron as a cause of neurodegenerative diseases?

Gerlach M, Ben-Shachar D, Riederer P, Youdim MB. Gerlach M, et al. Among authors: riederer p. J Neurochem. 1994 Sep;63(3):793-807. doi: 10.1046/j.1471-4159.1994.63030793.x. J Neurochem. 1994. PMID: 7519659 Review.

8

Neuroprotective therapeutic strategies. Comparison of experimental and clinical results.

Gerlach M, Riederer P, Youdim MB. Gerlach M, et al. Among authors: riederer p. Biochem Pharmacol. 1995 Jun 29;50(1):1-16. doi: 10.1016/0006-2952(95)00051-z. Biochem Pharmacol. 1995. PMID: 7605334 Review. No abstract available.

9

Is selegiline neuroprotective in Parkinson's disease?

Gerlach M, Youdim MB, Riederer P. Gerlach M, et al. Among authors: riederer p. J Neural Transm Suppl. 1994;41:177-88. doi: 10.1007/978-3-7091-9324-2_24. J Neural Transm Suppl. 1994. PMID: 7931225 Review.

10

Molecular mechanisms for neurodegeneration. Synergism between reactive oxygen species, calcium, and excitotoxic amino acids.

Gerlach M, Riederer P, Youdim MB. Gerlach M, et al. Among authors: riederer p. Adv Neurol. 1996;69:177-94. Adv Neurol. 1996. PMID: 8615127 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

838 results

Search Page

Filters